Li Ruo Yu, Wang A P, Xu J H, Xi L Y, Fu M H, Zhu M, Xu M L, Li X Q, Lai W, Liu W D, Lu X Y, Gong Z Q
Dermatology Department, Peking University First Hospital, 8# Xishiku Street, Xicheng District, Beijing, 100034, China,
Clin Drug Investig. 2014 Mar;34(3):223-30. doi: 10.1007/s40261-014-0171-8.
Superficial fungal skin infections are treated using topical antifungals. The aim of this study was to demonstrate the efficacy of a single application of 1 % terbinafine film-forming solution (FFS) versus placebo for the treatment of tinea pedis in the Chinese population.
Six centers in China randomized 290 patients in a 1:1 ratio to receive either 1 % terbinafine FFS or FFS vehicle (placebo) once on the affected foot/feet. Efficacy assessments included microscopy and mycologic culture, and assessing clinical signs and symptoms at baseline, and at weeks 1 and 6 after the topical treatment. All adverse events were recorded.
At week 6, 1 % terbinafine FFS was superior to placebo for effective treatment rate (63 vs. 8 %); clinical cure (30 vs. 6 %); mycological cure (86 vs. 12 %); negative microscopy (90 vs. 24 %); and negative mycological culture (90 vs. 27 %): all p ≤ 0.001 and clinically relevant. At week 6, 1 % terbinafine FFS was clinically superior to placebo for the absence of: erythema (69 vs. 29 %); desquamation (33 vs. 8 %); and pruritus (70 vs. 30 %): all p ≤ 0.001 and clinically relevant. At week 6, differences in the average total signs and symptoms scores were significantly lower for 1 % terbinafine FFS versus placebo (p ≤ 0.001). Both 1 % terbinafine FFS and placebo were safe and well tolerated based on adverse events and investigator and patient assessments.
This double-blind, randomized, multicenter study demonstrated one single topical application of 1 % terbinafine FFS was safe and effective in the treatment of tinea pedis in the Chinese population.
浅表真菌性皮肤感染采用外用抗真菌药物治疗。本研究的目的是证明单次应用1%特比萘芬成膜溶液(FFS)与安慰剂相比,在中国人群中治疗足癣的疗效。
中国的6个中心将290例患者按1:1比例随机分组,在患足上单次使用1%特比萘芬FFS或FFS赋形剂(安慰剂)。疗效评估包括显微镜检查和真菌培养,并在基线时以及局部治疗后第1周和第6周评估临床体征和症状。记录所有不良事件。
在第6周时,1%特比萘芬FFS在有效治疗率(63%对8%)、临床治愈率(30%对6%)、真菌学治愈率(86%对12%)、显微镜检查阴性率(90%对24%)和真菌培养阴性率(90%对27%)方面均优于安慰剂:所有p≤0.001,且具有临床相关性。在第6周时,1%特比萘芬FFS在无红斑(69%对29%)、脱屑(33%对8%)和瘙痒(70%对30%)方面临床疗效优于安慰剂:所有p≤0.001,且具有临床相关性。在第6周时,1%特比萘芬FFS与安慰剂相比,平均总体征和症状评分差异显著更低(p≤0.001)。基于不良事件以及研究者和患者评估,1%特比萘芬FFS和安慰剂均安全且耐受性良好。
这项双盲、随机、多中心研究表明,单次局部应用1%特比萘芬FFS在中国人群中治疗足癣安全有效。